Sodium-glucose cotransporter 2 inhibitors: The new option for diabetes mellitus management

Southern Medical Journal

Volumn 108, Issue 2, 2015, Pages 82-90

  Powell, Jason ^a   Miller, Shannon A ^a   Taylor, James R ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

canagliflozin; dapagliflozin; sodium glucose cotransporter proteins; type 2 diabetes mellitus

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; DIGOXIN; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; RIFAMPICIN; ROSIGLITAZONE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; SLC5A2 PROTEIN, HUMAN; THIOPHENE DERIVATIVE;

ADD ON THERAPY; DIET; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; EVENING DOSAGE; EXERCISE; FUNGAL GENITAL INFECTION; GLOMERULUS FILTRATION RATE; GLUCOSE ABSORPTION; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; KIDNEY TUBULE ABSORPTION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; EVIDENCE BASED MEDICINE; FEMALE; MALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TREATMENT OUTCOME;

BENZHYDRYL COMPOUNDS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; TREATMENT OUTCOME;

EID: 84923233298     PISSN: 00384348     EISSN: 15418243     Source Type: Journal    
DOI: 10.14423/SMJ.0000000000000233     Document Type: Review

References (29)

1. American Diabetes Association. Standards of medical care in diabetesV2014. Diabetes Care 2014;37(Suppl 1):S14YS80.
2. Chao EC, Henry RR. SGLT2 inhibitionVa novel strategy for diabetes treatment. Nat Rev Drug Discov 2010;9:551-559.
3. Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001;280:F10YF18.
4. Mackenzie B, Loo DD, Panayotova-Heiermann M, et al. Biophysical characteristics of the pig kidney Na+/glucose cotransporter SGLT2 reveal a common mechanism for SGLT1 and SGLT2. J Biol Chem 1996;271:32678-32683.
5. Kanai Y, Lee WS, You G, et al. The human kidney low affinity Na+/ glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994;93:397-404.
6. Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951;30:125-129.
7. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13:669-672.
8. Invokana (canagliflozin) [package insert]. Titusville, NJ, Janssen Pharmaceuticals, 2014.
9. Farxiga (dapagliflozin) [package insert]. Princeton, NJ, Bristol-Myers Squibb, 2014.
10. Stenlö f K, CefaluWT, KimKA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15: 372-382.
11. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35: 1232-1238.
12. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508-2515.
13. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013;15:463-473.
14. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012;14:539-545.
15. Bode B, Stenlöf K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995)2013;41:72-84.
16. Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2214-2224.
17. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomized, double-blind, placebo controlled trial. Lancet 2010;375: 2223-2233.
18. Nauck MA, Del Prato S,Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, doubleblind, active-controlled noninferiority trial. Diabetes Care 2011;34: 2015-2022.
19. Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011;13:928-938.
20. Wilding JP, Norwood P, T'joen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009;32:1656-1662.
21. Wilding JP,Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012;156:405-415.
22. Kaku K, Kiyosue A, Inoue S, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlledwith diet and exercise. DiabetesObesMetab 2014;16:1102-1110.
23. Ji L, Ma J, Li H, et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther2014;36:84-100. e9.
24. Bailey CJ, Iqbal N, T'joen C, et al. Dapagliflozin monotherapy in drugnaBve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab 2012;14:951-959.
25. Henry RR, Murray AV, Marmolejo MH, et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012;66:446-456.
26. Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35:1473-1478.
27. Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 2014;37:740-750.
28. Anderson SL, Marrs JC. Dapagliflozin for the treatment of type 2 diabetes. Ann Pharmacother 2012;46:590-598.
29. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Translational Sciences, Office of Biostatistics. Statistical review and evaluation: clinical studies. http://www. accessdata. fda. gov/drugsatfda- docs/nda/2014/202293Orig1s000StatR. pdf. Accessed June 26, 2014.